real-world-benefit-shown-in-T2D-treatment
Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
Search
Circular economy: Taking action to reduce plastic waste
The packaging department team at Yamagata, Japan, managed to reduce their waste plastic material for a greener and more sustainable tomorrow
cat feline diabetes medication treatment fda approval
Boehringer Ingelheim receives FDA approval for SENVELGO®
preserved-heart-failure-treatment-approval-europe
preserved-heart-failure-treatment-approval-europe
Pascal Haubert
After three months of interning with us, Pascal Haubert talks about the importance of taking responsibility, learning and mutual support.
Grilled Hawaiian Beef Kabobs
A delicious recipe made with layers of tender steak, juicy pineapple and fresh vegetables from Taking Cancer on Through Flavour and Taste Life. Find out how to make this recipe here.
emperor-reduced-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction
FDA-Fast-Track-chronic-kidney-disease
FDA grants Fast Track designation for the treatment of chronic kidney disease, underscoring urgent need for new treatments for people living with the condition
empa-reg-outcome-recurrent-events
EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
Making a difference with data science
Our Head of Central Data Science, Brigitte Fuhr joined the team to make a difference to patients’ lives.
FDA approval NexGard PLUS for dogs
Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS - A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
DCRI-collaboration-empact-mi
Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
emperor-preserved-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction
empulse-trial-benefit-acute-heart-failure
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
emperor-preserved-chmp-positive-opinion
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
Anna Race
Human Pharma's Sales Director for UK & Ireland, Anna Race discusses how she enjoys making a difference within the company.
EMPRISE-interim-analysis
Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
EMPERIAL-heart-failure-toplineresults
Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction
emperor-preserved-kidney-subanalysis
New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
emperor-preserved-heart-failure-full-data
Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
Phase 3 studies survodutide obesity and overweight
Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
China pioneers biosecurity report against ASF
Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.
Largest European development center for biotechnology
Boehringer Ingelheim inaugurates largest European development center for biotechnology
Digital solutions save lives
Michael Schmelmer explains how digital solutions shape the future of Boehringer Ingelheim and the entire healthcare industry.